Nominate an industry leader for recognition they deserve


Tuesday, 24 September, 2013

The 2013 Janssen Industry Excellence Awards close this Friday 27 September. This is the last chance in 2013 to nominate an individual or organisation that has made a significant contribution to the biotechnology industry and, through their leadership, continues to make a difference to the growth of the bio-economy in Australia.

The annual Janssen Industry Excellence Awards recognise the standard-bearers for excellence in the Australian biotechnology industry. Nominations for the 2013 awards in three categories close for nomination on Friday:

  • Industry Leadership Award: This award seeks candidates who have already made a significant difference to the industry and have an outstanding commitment to life sciences/biotechnology that often goes beyond the ‘job description’. Candidates will be known for their passion, enthusiasm and commitment to the industry in Australia.
  • Australian Company of the Year Award: The Australian Company of the Year will be awarded to a company that has demonstrated significant achievement/s and may include any company working in biotechnology or life sciences, including but not limited to the medical diagnostics or devices, pharmaceutical and agricultural biotechnology sectors. Criteria for companies may include deals done, product pipeline, IP, company strategy and/or revenue.
  • Australian Emerging Company of the Year Award: The Emerging Company of the Year award will be based on the same criteria as above, but be specific to companies under five years of age.

Nominations of up to 400 words are invited, outlining why the nominated individual/company should be awarded a Janssen 2013 Industry Excellence Award according to the applicable category and criteria.

Please forward nominations to Kirsty Whitehead, Conference & Event Manager, AusBiotech, kwhitehead@ausbiotech.org. Nominations close Friday 27 September 2013.

For further information and entry criteria, please refer to the AusBiotech 2013 national conference website.

Related News

Cancer drug eliminates bone metastasis in lab models

Researchers have developed a novel treatment that is specific to breast cancer bone metastasis...

TGA rejects Alzheimer's drug due to safety concerns

The TGA determined that the demonstrated efficacy of lecanemab in treating Alzheimer's did...

Defective sperm doubles pre-eclampsia risk in IVF patients

A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd